Collection
MeSH Terms
Breast Neoplasms, breast tumor, breast cancer, breast neoplasm, Diphosphonates, bisphosphonic acid derivative, bisphosphonate, zoledron, ibandron, pamidron, risedron, alendron, neridron, olpadron, clodron, tiludron, etidron, reclast, zometa, aclasta, boniva, aredia, actonel, fosamax, nerixia, bonefos, loron, skelid, didronel, Bone Density Conservation Agents, Endothelin A Receptor Antagonists, denosumab, calcitonin, dasatinib, rilotumumab, cabozantinib, bone-modifying agent, atrasentan, zibotentan, dasatinib, rilotumumab, AMG102, cabozantinib, Prolia, Xgeva, Fortical, Miacalicin, Evista
Keywords
breast neoplasms, breast cancer, diphosphonates, bisphosphonate, bone-modifying agent, adjuvant therapy
Date for Review
In Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario), we have an annual review process for each guideline after it is completed. Guidelines are reviewed every fall after they are older than 1 year.
Record Publish Year
2022
Publication Date
2022-07-14
Date of Last Evidence Search
2021-01-28
Methods Applied
Evidence-based,
Systematic review-based,
Externally reviewed,
Evidence quality assessmen
Systematic review-based,
Externally reviewed,
Evidence quality assessmen
Guideline Contact
Glenn Fletcher; pebconc@mcmaster.ca
Publication Scope
Guidelines
treatment
Countries of Application
Canada
Guideline Publication Status
Published
Languages
English
Authors
PEBC (Program in evidenced-based care)
Publication Year
2022